Two Bugs a NOD Away from Improving Cancer Therapy Efficacy

Romina E Araya; Romina S Goldszmid

doi:10.1016/j.immuni.2016.10.007

Two Bugs a NOD Away from Improving Cancer Therapy Efficacy

Immunity. 2016 Oct 18;45(4):714-716. doi: 10.1016/j.immuni.2016.10.007.

Authors

Romina E Araya¹, Romina S Goldszmid²

Affiliations

¹ Inflammatory Cell Dynamics Section, Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA.
² Inflammatory Cell Dynamics Section, Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA. Electronic address: [email protected].

PMID: 27760335
DOI: 10.1016/j.immuni.2016.10.007

Abstract

It has recently become apparent that the gut microbiota modulates the response to cancer therapy. In this issue of Immunity, Daillère et al. (2016) identified two bacterial species potentiating the anti-tumor effect of cyclophosphamide that are kept in check by the sensor NOD2.

Published by Elsevier Inc.

Publication types

Review
Research Support, N.I.H., Intramural
Comment

MeSH terms

Animals
Bacteria / metabolism*
Cyclophosphamide / pharmacology
Cyclophosphamide / therapeutic use
Gastrointestinal Microbiome / physiology*
Humans
Neoplasms / drug therapy
Neoplasms / microbiology*
Nod2 Signaling Adaptor Protein / metabolism*

Substances

Nod2 Signaling Adaptor Protein
Cyclophosphamide